5823-51-8

Usage

Uses

Used in Chemical Industry:
[1,2,5]Thiadiazolidine 1,1-Dioxide is used as a chemical intermediate for the synthesis of various compounds due to its reactive nature and ability to form a variety of chemical bonds.
Used in Pharmaceutical Industry:
[1,2,5]Thiadiazolidine 1,1-Dioxide is used as a building block in the development of new pharmaceutical compounds, leveraging its unique structure to create novel drug candidates with potential therapeutic applications.
Used in Research and Development:
[1,2,5]Thiadiazolidine 1,1-Dioxide serves as a valuable research tool in the study of heterocyclic chemistry, allowing scientists to explore new reaction pathways and investigate the properties of related compounds.

InChI:InChI=1/C7H6N2O/c8-4-5-3-6(9)1-2-7(5)10/h1-3,10H,9H2

Upstream product

• 107-15-3 ethylenediamine 
• 7803-58-9 SULFAMIDE 
• 144432-72-4 2-benzyl-1,2,5-thiadiazolidine 1,1-dioxide 
• 67104-91-0 2,5-di-tert-butyl-[1,2,5]thiadiazolidine 1,1-dioxide 

Downstream Products

• 1092980-94-3 C₈H₈FN₃O₄S 
• 1237802-47-9 C₂₃H₂₃F₅N₂O₅S₂ 

Relevant academic research and scientific papers

Discovery of New Imidazo[2,1- b]thiazole Derivatives as Potent Pan-RAF Inhibitors with Promising in Vitro and in Vivo Anti-melanoma Activity

BRAF is an important component of MAPK cascade. Mutation of BRAF, in particular V600E, leads to hyperactivation of the MAPK pathway and uncontrolled cellular growth. Resistance to selective inhibitors of mutated BRAF is a major obstacle against treatment of many cancer types. In this work, a series of new (imidazo[2,1-b]thiazol-5-yl)pyrimidine derivatives possessing a terminal sulfonamide moiety were synthesized. Pan-RAF inhibitory effect of the new series was investigated, and structure-activity relationship is discussed. Antiproliferative activity of the target compounds was tested against the NCI-60 cell line panel. The most active compounds were further tested to obtain their IC50 values against cancer cells. Compound 27c with terminal open chain sulfonamide and 38a with a cyclic sulfamide moiety showed the highest activity in enzymatic and cellular assay, and both compounds were able to inhibit phosphorylation of MEK and ERK. Compound 38a was selected for testing its in vivo activity against melanoma. Cellular and animal activities are reported.

Carbazole-containing sulfonamides and sulfamides: Discovery of cryptochrome modulators as antidiabetic agents

A series of novel carbazole-containing sulfonamides and sulfamides were synthesized. A structure-activity relationship study of these compounds led to the identification of potent cryptochrome modulators. Based on the results of efficacy studies in diet-induced obese (DIO) mice, and the desired pharmacokinetic parameters, compound 41 was selected for further profiling.

Carbazole-Containing Sulfonamides as Cryptochrome Modulators

The subject matter herein is directed to carbazole-containing sulfonamide derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R1, R2, R3, R4, R5, R6, R7, A, B, C, D, E, F, G, H, a, and b are accordingly described. Also provided are pharmaceutical compositions comprising the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, obesity, metabolic syndrome, Cushing's syndrome, and glaucoma.

Synthesis and antibacterial activities of novel oxazolidinones having cyclic sulfonamide moieties

The synthesis of a new series of oxazolidinones having cyclic sulfonamide moieties is described. Their in vitro antibacterial activities against both Gram-positive and Gram-negative bacteria were tested and the effect of substituents on the oxazolidinone

Synthesis and Biological Activity of 3--5--1H-indole and Analogues: Agonists for the 5-HT1D Receptor

A novel series of 5-(1,1-dioxo-1,2,5-thiadiazolidin-2-yl)tryptamines was designed, synthesized, and evaluated as 5-HT1D receptor agonists.Compounds such as 8d,f,k were identified which had comparable affinity, potency, and receptor selectivity